Organization | Hope Cancer Institute, Inc.

Hope Cancer Institute, Inc. Report issue

Academic/Hospital Phase 2

Founded: Kansas City KS United States (1997)

Organization Overview

First Clinical Trial

1997

NCT00003183

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1998

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (8)

aldesleukin (Proleukin) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

mitoxantrone (novantrone) (1 trial)

sargramostim (leukine) (2 trials)

vinblastine (velban) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Renal Cell (Phase 2)

Head and Neck Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 8